PCR32 Bimekizumab Improves Work Productivity in Patients With Hidradenitis Suppurativa: 2-Year Results From BE HEARD EXT

Document Type

Conference Proceeding

Publication Date

12-1-2025

Publication Title

Value Health

Keywords

bimekizumab, immunoglobulin G1, interleukin 17F, absenteeism, adult, chronic inflammation, conference abstract, controlled study, dermatitis, drug combination, female, human, major clinical study, male, middle aged, presenteeism, quality of life, randomized controlled trial, suppurative hidradenitis, work productivity and activity impairment questionnaire

Abstract

Objectives: Hidradenitis suppurativa (HS), a chronic inflammatory skin disease with debilitating symptoms, significantly impacts patients’ quality of life and work productivity.1 Bimekizumab (BKZ) is a humanised IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.2 This publication demonstrates how long-term BKZ treatment of patients with moderate to severe HS impacts work productivity. Methods: Patients randomised to BKZ from baseline in BE HEARD I&II and who entered their open-label extension (OLE), BE HEARD EXT, were pooled (BKZ Total; OLE set).3,4 Patients completed the Work Productivity and Activity Impairment (WPAI) Questionnaire at various timepoints that included baseline, Week48 and Week96. For the domains, the percentage of overall work impairment, impairment while working (presenteeism), work time missed (absenteeism) and activity impairment were calculated: mean absolute scores are reported; higher scores indicate greater impairment.5 All domains except activity impairment were answered only by patients who were employed. Data are reported as observed case. Results: 556 patients randomised to BKZ at baseline in BE HEARD I&II completed Week48 and entered BE HEARD EXT. BKZ Total patients reported an improved (reduced) mean (SD;n) overall work impairment score over 48 weeks, which was sustained to Week96 (baseline: 29.6%[27.4;338]; Week48: 14.6%[20.4;408]; Week96: 16.0%[20.8;309]). Similarly, improvements in presenteeism (baseline: 28.7%[26.4;338]; Week48: 12.6%[18.1;408]; Week96: 12.5%[17.7;309]) and activity impairment (baseline: 39.9%[28.6;551]; Week48: 16.5%[21.3;555]; Week96: 17.1%[21.8;439]) were also observed. Absenteeism remained consistently low over 96 weeks (baseline: 5.5%[18.8;349]; Week48: 4.8%[17.3;415]; Week96: 5.6%[17.6;314]). Conclusions: In patients with HS treated with bimekizumab, 1-year improvements in work productivity which included overall work impairment, presenteeism and activity impairment, were maintained to 2 years; absenteeism remained low. References: 1. Zouboulis CC et al. 2015;231:184-90; 2. Adams R et al. 2020;11:1894; 3. Kimball AB et al. 2024 (NCT04242446, NCT04242498); 4. BE HEARD EXT: www.clinicaltrials.gov/study/NCT04901195 (NCT04901195); 5. Zhang W et al. 2010;12:R177.

Volume

28

Issue

12

First Page

S551

Last Page

S552

Find It @ Sladen

Share

COinS